Salma K. Jabbour, MD, Discusses the Value of Treating Patients With NSCLC in a Multidisciplinary Setting

Jabbour detailed the importance of managing care in a multidisciplinary setting for patients enrolled in the KEYNOTE-799 trial with stage III NSCLC.

CancerNetwork® sat down with Salma K. Jabbour, MD, of the Rutgers Cancer Institute of New Jersey, to discuss how patients with stage III non–small cell lung cancer (NSCLC) treated on the phase 2 KEYNOTE-799 trial (NCT03631784) that was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting can benefit from a multidisciplinary approach to care.

In the trial, patients with unresectable, locally advanced NSCLC were treated with pembrolizumab plus platinum doublet chemotherapy and radiotherapy followed by pembrolizumab monotherapy.

Transcription:

It's really important for [patients with stage III NSCLC] to be evaluated in a multidisciplinary setting and to be managed in a multidisciplinary setting and it is very much a team approach from the onset of the patient's care. I think that really can't be underestimated because these patients require a lot of attention and care to make sure that their treatment really goes smoothly and [adverse] effects from chemoradiation can be managed, such as esophagitis, dermatitis, and pneumonitis. That is really an important component. The communication with the team, both from the medical oncologist, the radiation oncologist, and initial involvement from the surgeon make the determination about resectability. All of it is really important and helps to carry the patient through with a tolerable toxicity profile and…have them achieve a successful and manageable therapy.

Reference

Jabbour SK, Lee H, Frost N, et al. KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC. J Clin Oncol. 2021;39(suppl 15):8512. doi:10.1200/JCO.2021.39.15_suppl.8512.

Related Videos
Experts on non-small cell lung cancer
A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.
Experts on non-small cell lung cancer
Experts on non-small cell lung cancer
Patients who use a recovery tracker tool appear to experience lower hospital readmission rates following gynecologic cancer debulking surgery compared with those who did not.
Medical oncologists and gynecologic oncologists alike have a shared responsibility to help treat symptoms of neuropathy in patients undergoing chemotherapy for gynecologic cancer, according to an expert from Duke University Medical Center.
Experts on non-small cell lung cancer
Experts on non-small cell lung cancer
Future research assessing cryocompression for those with gynecologic cancers will make use of different products to make the intervention easier and more accessible for patients.
Related Content